Arvela Eva, Venermo Maarit, Söderström Maria, Albäck Anders, Lepäntalo Mauri
Department of Vascular Surgery, Helsinki University Central Hospital, Helsinki, Finland.
Ann Vasc Surg. 2012 Apr;26(3):396-403. doi: 10.1016/j.avsg.2011.08.013. Epub 2012 Jan 27.
Single-segment great saphenous vein (ssGSV) is the conduit of choice in infrainguinal bypass for critical limb ischemia (CLI). The aim of this study was to assess results of other autologous vein grafts and risk factors for graft stenosis development and graft failure. The purpose was also to evaluate outcome of patients with high operative risk undergoing infrainguinal alternative autologous vein bypass for CLI.
We retrospectively reviewed 1,109 consecutive infrainguinal bypasses performed between 2000 and 2007 for CLI. Rate and type of operations needed to maintain graft patency were evaluated. Outcome of different types of vein grafts in terms of primary patency, assisted primary patency, secondary patency, and limb salvage was assessed using Kaplan-Meier method. Predictors of poor outcome as well as patient- and graft-related risk factors for graft revision and graft failure were analyzed using multivariate analysis.
Median follow-up period was 37 (0-121) months. Primary patency, assisted primary patency, secondary patency, and limb salvage at 1 and 3 years were significantly better in ssGSV graft group than in alternative autologous vein graft (AAVG) group-74.4% and 67.1% versus 53.7% and 42.0% (P < 0.0001), 82.8% and 78.2% versus 67.2% and 57.8% (P < 0.0001), 84.8% and 80.8% versus 69.9% and 61.4% (P < 0.0001), and 88.9% and 86.9% versus 83.0% and 77.2% (P < 0.0001), respectively. In multivariate analysis, non-ssGSV graft was the only independent risk factor for the graft stenosis development (relative risk [RR]: 2.62, 95% confidence interval [CI]: 1.56-4.38, P < 0.0001), for graft occlusion (RR: 2.27, 95% CI: 1.52-3.40, P < 0.0001), and for graft failure (stenosis or occlusion) (RR: 2.00, 95% CI: 1.39-2.88, P < 0.0001). Revision rate of non-ssGSV conduits was higher than that of ssGSV grafts (18% vs. 12%, P = 0.007). High-risk patients (age of >80 years, coronary artery disease, estimated glomerular filtration rate of <30 mL/min/1.73 m(2)) who underwent bypass with arm vein or spliced vein had extremely poor outcome (1-year leg salvage rate and survival rate of 71.4% and 28.6%, respectively).
The ssGSV graft is superior to any other autologous vein graft in terms of midterm patency and leg salvage. It also needs less maintenance procedures than AAVGs. Non-ssGSV graft is independent predictor of both graft stenosis development and graft failure. Acceptable patency and leg salvage rates can also be achieved with AAVGs. However, patients with high operative risk and non-ssGSV graft bypass have poor outcome.
单节段大隐静脉(ssGSV)是下肢严重缺血(CLI)患者腹股沟下旁路移植术的首选血管。本研究旨在评估其他自体静脉移植物的效果以及移植物狭窄和失败的危险因素。同时评估接受腹股沟下自体静脉旁路移植术的高危CLI患者的预后。
我们回顾性分析了2000年至2007年间连续进行的1109例腹股沟下旁路移植术治疗CLI的患者。评估维持移植物通畅所需的手术率和类型。采用Kaplan-Meier法评估不同类型静脉移植物的一期通畅率、辅助一期通畅率、二期通畅率和肢体挽救率。使用多因素分析评估预后不良的预测因素以及移植物翻修和失败的患者及移植物相关危险因素。
中位随访期为37(0 - 121)个月。ssGSV移植物组1年和3年的一期通畅率、辅助一期通畅率、二期通畅率和肢体挽救率均显著优于其他自体静脉移植物(AAVG)组,分别为74.4%和67.1% 对比53.7%和42.0%(P < 0.0001),82.8%和78.2%对比67.2%和57.8%(P < 0.0001),84.8%和80.8%对比69.9%和61.4%(P < 0.0001),88.9%和86.9%对比83.0%和77.2%(P < 0.0001)。多因素分析显示,非ssGSV移植物是移植物狭窄(相对危险度[RR]:2.62,95%置信区间[CI]:1.56 - 4.38,P < 0.0001)、移植物闭塞(RR:2.27,95% CI:1.52 - 3.40,P < 0.0001)和移植物失败(狭窄或闭塞)(RR:2.00,95% CI:1.39 - 2.88,P < 0.0001)的唯一独立危险因素。非ssGSV血管的翻修率高于ssGSV移植物(18%对比12%,P = 0.007)。接受臂静脉或拼接静脉旁路移植术的高危患者(年龄>80岁、冠状动脉疾病、估计肾小球滤过率<30 mL/min/1.73 m²)预后极差(1年肢体挽救率和生存率分别为71.4%和28.6%)。
就中期通畅率和肢体挽救而言,ssGSV移植物优于任何其他自体静脉移植物。与AAVG相比,其所需的维护程序也更少。非ssGSV移植物是移植物狭窄和失败的独立预测因素。AAVG也可实现可接受的通畅率和肢体挽救率。然而,手术风险高且采用非ssGSV移植物进行旁路移植术的患者预后较差。